Clinical Trial

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

Name: Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases — clinical trial record (NCT07277322)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This Phase 1b/2 trial will evaluate the safety and efficacy of neoadjuvant immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) subjects with resectable liver metastases.

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-13

Trial Details

NCT Number	NCT07277322
Lead Sponsor	Dan Feng Collaborators: Coherus Oncology, Inc.
Conditions	Metastatic Colorectal Cancer, Liver Metastases
Enrollment	24 participants
Start Date	2026-09-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-12